
## Angelo A Bignamini

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4507108/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Sulodexide for the Prevention of Recurrent Venous Thromboembolism. Circulation, 2015, 132, 1891-1897.	1.6	109
2	Age and origin of the FCMD 3′-untranslated-region retrotransposal insertion mutation causing Fukuyama-type congenital muscular dystrophy in the Japanese population. Human Genetics, 2000, 107, 559-567.	3.8	30
3	Sulodexide for the Symptoms and Signs of Chronic Venous Disease: A Systematic Review and Meta-analysis. Advances in Therapy, 2020, 37, 1013-1033.	2.9	27
4	Lessons Learned From a Randomized Study of Oral Valganciclovir Versus Parenteral Ganciclovir Treatment of Cytomegalovirus Disease in Solid Organ Transplant Recipients: The VICTOR Trial. Clinical Infectious Diseases, 2016, 62, 1154-1160.	5.8	24
5	Sulodexide for Diabetic-Induced Disabilities: A Systematic Review and Meta-Analysis. Advances in Therapy, 2021, 38, 1483-1513.	2.9	18
6	Metadoxine Versus Placebo for the Treatment of Non-alcoholic Steatohepatitis: A Randomized Controlled Trial. Journal of Clinical and Experimental Hepatology, 2014, 4, 94-100.	0.9	16
7	Editor's Choice – PRINciples of optimal antithrombotiC therapy and coagulation managEment during elective fenestrated and branched EndovaScular aortic repairS (PRINCE2SS): An International Expert Based Delphi Consensus Study. European Journal of Vascular and Endovascular Surgery, 2022, 63, 838-850.	1.5	15
8	Novel decay dynamics revealed for virus-mediated drug activation in cytomegalovirus infection. PLoS Pathogens, 2017, 13, e1006299.	4.7	12
9	Pharmacological adjuncts for chronic venous ulcer healing. Phlebology, 2016, 31, 366-367.	1.2	10
10	Design and rationale of a randomized, placebo-controlled trial on the efficacy and safety of sulodexide for extended treatment in elderly patients after a first venous thromboembolism. Internal and Emergency Medicine, 2021, 16, 359-368.	2.0	3
11	Extended use of sulodexide, apixaban, rivaroxaban and dabigatran in venous thromboembolism: indirect comparison of clinical trials. International Angiology, 2017, 36, 496-497.	0.9	2
12	Investigation of Health-Related Quality of Life Outcomes in Cancer Patients: Findings from an Observational Study Using the EQ-5D in Italy. SN Comprehensive Clinical Medicine, 2020, 2, 1579-1584.	0.6	2
13	Influence of clinical presentation, site, and extent of venous thrombosis on decision about duration of anticoagulation: Data from the international, prospective, observational WHITE study. Thrombosis Research, 2022, 211, 140-146.	1.7	2